|
|
|
| Meta analysis of efficacy and safety of drug-eluting beads transarterial chemoembolization and conventional transarterial chemoembolization in the treatment of advanced hepatocellular carcinoma |
| CAO Bo1 ZHANG Guangwen2 |
1.The First Clinical College, Xinxiang Medical University, Henan Province, Xinxiang 453000, China;
2.Department of Infectious Diseases, the First Affiliated Hospital of Xinxiang Medical University, Henan Province, Xinxiang 453000, China |
|
|
|
Abstract Objective To compare the efficacy and safety of drug-eluting beads transarterial chemoembolization (DEB-TACE) and conventional transarterial chemoembolization (cTACE) in the treatment of advanced hepatocellular carcinoma. Methods PubMed, EMbase, Cochrane library, CNKI, Wanfang and VIP databases were searched for the randomized controlled trials(RCT) of DEB-TACE and cTACE in the treatment of advanced hepatocellular carcinoma. The retrieval period was from establishment of the database to June 2020, and the data were analyzed by Stata 15.1 software. The disease control rate (DCR) after treatment,1-year survival rate, 2-year survival rate and adverse reaction rate were observed. Results A total of 13 RCTs with 1478 patients were included. The DCR after treatment of DEB-TACE group was higher than that of cTACE group, and the difference was statistically significant (OR = 2.18, 95%CI: 1.49-3.19, P < 0.001). The 1-year survival rate of DEB-TACE group was higher than that of cTACE group, and the difference was statistically significant (OR = 1.91, 95%CI: 1.32-2.75, P = 0.001). The 2-year survival rate of DEB-TACE group was higher than that of cTACE group, and the difference was statistically significant (OR = 1.70, 95%CI: 1.16-2.50, P = 0.006). There was no significant difference in the rate of adverse reactions between two groups (OR = 0.74, 95%CI: 0.53-1.02, P = 0.068). Conclusion DEB-TACE has better efficacy than cTACE in the treatment of advanced hepatocellular carcinoma, and its safety is not inferior to cTACE.
|
|
|
|
|
|
[1] Ferlay J，Soerjomataram I，Dikshit R，et al. Cancer incidence and mortality worldwide：Sources，methods and major patterns in GLOBOCAN 2012 [J]. Int J Cancer，2015， 136（5）：359-386.
[2] Song MJ，Bae SH. Newer treatments for advanced hepatocellular carcinoma [J]. Korean J Intern Med，2014，29（2）：149-155.
[3] Torre LA，Bray F，Siegel RL，et al. Global cancer statistics，2012 [J]. CA Cancer J Clin，2015，65（2）：87-108.
[4] 安天志，高嵩，靳勇，等.中国肝细胞癌经动脉化疗栓塞治疗临床实践指南[J].中华介入放射学电子杂志，2019， 7（3）：178-184.
[5] Grosso M，Vignali C，Quaretti P，et al. Transarterial Chemoembolization for Hepatocellular Carcinoma with Drug-Eluting Microspheres：Preliminary Results from an Italian Multicentre Study [J]. Cardiovasc Intervent Radiol，2008，31（6）：1141-1149.
[6] Xie ZB，Wang XB，Peng YC，et al. Systematic review comparing the safely and efficacy of conventional and drug-eluting bead transarterial chemoembolization for inoperable hepatocellular carcinoma [J]. Hepatol Res，2015，45（2）：190-200.
[7] Lencioni R，Llovet JM. Modified RECIST（mRECIST） assessment for hepatocellular carcinoma [J]. Semin Liver Dis，2010，30（1）：52-60.
[8] Lammer J，Malagari K，Vog T，et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma：results of the PRECISION V study [J]. Cardiovasc Intervent Radiol，2010， 33（1）：41-52.
[9] Sacco R，Bargellini I，Bertin M，et al. Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma [J]. Vasc Interv Radiol，2011， 22（11）：1545-1552.
[10] Golfieri R，Giampalma E，Renzulli M，et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma [J]. Br J Cancer，2014，111（2）：255-264.
[11] 王忠，刘启榆，杨伟，等.国产CalliSpheres载药微球DEB-TACE治疗无法手术肝癌的临床价值[J].肝脏，2019， 24（7）：767-770.
[12] 李富永，孙玉敏，石明波.载药微球及超液化碘油用于肝癌肝动脉栓塞术的价值比较[J].现代消化及介入诊疗，2020，25（5）：649-652.
[13] 王玥珵.载药微球经导管动脉化疗栓塞治疗肝癌的安全性分析[J].微创医学，2020，15（3）：295-297.
[14] 孙向阳.载药微球经肝动脉化疗栓塞治疗原发性肝癌的多因素疗效评价[D].济南：山东大学，2020.
[15] 黄英杰，凌永志，秦梓良，等.HepaSphere载药微球治疗原发性肝癌的效果评价[J].临床医学，2018，38（1）：35-36.
[16] 黄振，苏国锋，张立波.Embosphere微球多次动脉化疗栓塞治疗中晚期肝癌患者临床效果观察[J].内科，2020， 15（2）：170-172，185.
[17] 王会品，张丽红，李雷可.多柔比星载药微球经导管动脉化疗栓塞治疗肝癌临床疗效观察[J].中国药师，2018， 21（4）：654-656.
[18] 陈元，魏晓艳，曹凯，等.药物洗脱微球经肝动脉化疗栓塞术治疗中晚期原发性肝癌的疗效[J].中国肿瘤临床与康复，2017，24（6）：711-714.
[19] 蒲长宇，陈琦.载药微球用于中晚期肝癌TACE术对肝功能及免疫功能的影响[J].肝脏，2020，25（1）：42-46.
[20] 池琦，张玲玲，刘彬，等.表柔比星分别联合碘油与Hepasphere载药微球对肝癌患者TACE的疗效分析[J].现代肿瘤医学，2018，26（13）：2090-2093.
[21] Yang B，Liang J，Qu Z，et al. Transarterial strategies for the treatment of unresectable hepatocellular carcinoma：A systematic review [J]. PLoS One，2020，15（2）：e0227475.
[22] Han T，Yang X，Zhang Y，et al. The clinical safety and efficacy of conventional transcatheter arterial chemoembolization and drug-eluting beads-transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma：A meta-analysis [J]. Biosci Trends，2019，13（5）：374-381.
[23] Lencioni R，de Baere T，Soulen MC，et al. Lipiodol transarterial chemoembolization for hepatocellular carcinoma：A systematic review of efficacy and safety data [J]. Hepatology，2016，64（1）：106-116.
[24] Huppert P. Current concepts in transarterial chemoembolization of hepatocellular carcinoma [J]. Abdom Imaging，2011，36（6）：677-683.
[25] Sattler T，Bredt C，Surwald S，et al. Efficacy and Safety of Drug Eluting Bead TACE with Microspheres <150 mum for the Treatment of Hepatocellular Carcinoma [J]. Anticancer Res，2018，38（2）：1025-1032.
[26] Albrecht KC，Aschenbach R，Diamantis I，et al. Response rate and safety in patients with hepatocellular carcinoma treated with transarterial chemoembolization using 40-microm doxorubicin-eluting microspheres [J]. J Cancer Res Clin Oncol，2021,147（1）：23-32.
[27] Schicho A，Hellerbrand C，Kruger K，et al. Impact of Different Embolic Agents for Transarterial Chemoembolization（TACE）Procedures on Systemic Vascular Endothelial Growth Factor（VEGF）Levels [J]. Clin Transl Hepatol，2016，4（4）：288-292. |
|
|
|
